Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study, led by Professor Kim Dora in association with Professor Raimondo Ascione at the University of Bristol, has shown abnormalities in the tiny blood vessels of human hearts which cannot be detected by current heart scans. Poor myogenic (automatic) tone, where blood flow in these vessels is abnormal, is thought to develop independent of disease in the larger arteries, which can be treated using stents or bypass surgeries.

This study, funded by the British Heart Foundation, used tissue biopsies to study the function, structure and alterations in pathways in the micro-arteries that link to abnormalities in myogenic tone. The research team found that 44 per cent of the micro-arteries, from patients with no large coronary artery blockages and undergoing valvular cardiac surgery, had abnormal myogenic tone despite retaining their cell viability. This abnormality was associated with an excessive presence of a molecule called caldesmon within the muscle cells in the wall of the abnormal micro-arteries and with poor alignment of these contracting cells compared to micro-arteries with normal myogenic tone.

Kim explained: “Not only will our findings enhance the development of new medical treatments and possibly new patient imaging modalities, but they represent a new ex-vivo research model for thousands of scientists globally working on microvascular dysfunction in the heart and other organs.”

Full details can be found in the new paper published in Cardiovascular Research

Similar stories

Anthony group research offers new treatment hope for ALS patients

New research, led by the Anthony Group in Pharmacology and funded by GeNeuro, suggests a pathway to a new precision medicine approach for patients with amyotrophic lateral sclerosis (ALS). The groundbreaking findings were presented at the 35th International Symposium on ALS/MND, which took place in Montreal, Canada, from 6-8 December 2024.